News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
Clinical - Phase III
XOMA (US) LLC (XOMA) Initiates U.S. Clinical Trial Of Gevokizumab In Patients With Behcet's Disease Uveitis - EYEGUARD™-U.S. 10/1/2014
Zafgen (ZFGN) Announces Initiation Of Phase 3 Trial Of Beloranib In Prader-Willi Syndrome 10/1/2014
ERYtech Pharma Reports Positive Top-Line Phase III Results From Clinical Study With GRASPA® In Acute Lymphoblastic Leukemia 10/1/2014
Novartis AG (NVS) To Roll Out 15 Abstracts At EADV 10/1/2014
Shionogi, Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC 10/1/2014
Alnylam Pharmaceuticals (ALNY) Initiates EXPLORE, A Prospective Observational Study Of Patients With Hepatic Porphyrias 10/1/2014
Portola Pharmaceuticals, Inc.'s ANNEXA™ Reverses Effect Of Anti-Clotting Drugs In Phase 3 Study 10/1/2014
TherapeuticsMD, Inc.  (TXMD) Begins Phase 3 Clinical Trial Of TX-004HR (VagiCapTM) For The Treatment Of Painful Intercourse, A Symptom Of VVA, Due To Menopause 9/30/2014
Salix Pharmaceuticals, Ltd. (SLXP) Release: FDA Approves RELISTOR® Subcutaneous Injection For The Treatment Of Opioid-Induced Constipation In Patients With Chronic Non-cancer Pain 9/30/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 9/29/2014
Genentech (RHHBY)’s Investigational Combination Of Cobimetinib Plus Zelboraf (Vemurafenib) Provided Significant Benefit To People With Advanced Melanoma Over Zelboraf Alone 9/29/2014
Seattle Genetics, Inc. (SGEN) To Host Conference Call And Webcast On September 29, 2014 Regarding Top-Line Data From ADCETRIS® (brentuximab vedotin) Phase 3 AETHERA Clinical Trial 9/29/2014
Seattle Genetics, Inc. (SGEN) And Takeda Pharmaceutical Co. Ltd. (TKPYY) Announce Positive Data From Phase 3 AETHERA Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) For Consolidation In Post-Transplant Hodgkin Lymphoma 9/29/2014
Seattle Genetics, Inc. (SGEN), Takeda Pharmaceutical Co. Ltd. (TKPYY)'s Cancer Drug Meets Main Goal In Phase 3 Trial 9/29/2014
Novartis AG (NVS) Drug Afinitor Is First Treatment For Advanced Pancreatic NET To Provide Overall Survival Of More Than 3.5 Years In Phase 3 Trial 9/29/2014
Janssen Research & Development Release: ZYTIGA® Plus Prednisone Demonstrates Statistically Significant Overall Survival After 49-Month Follow-Up Analysis In Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer 9/29/2014
Keryx Biopharmaceuticals (KERX) Initiates Pivotal Phase 3 Study Of Ferric Citrate For The Treatment Of Iron Deficiency Anemia In Patients With Non-Dialysis Dependent Chronic Kidney Disease 9/29/2014
Agile Therapeutics, Inc. Announces Dosing Of First Patients In Twirla® Phase 3 SECURE Study 9/29/2014
Janssen Pharmaceutical Inc. Release: ZYTIGA®* Plus Prednisone Demonstrates Statistically Significant Overall Survival In Men With Advanced Prostate Cancer Prior To Chemotherapy 9/29/2014
Boehringer Ingelheim Corporation's Afatinib Meets Primary Endpoint In Phase 3 Study Of Head And Neck Cancer 9/29/2014
SALVAT Announces Positive Top-Line Results From Two Phase 3 Studies Of Its Novel Otic Antibiotic/Steroid Combination Solution In The Treatment Of AOMT With Tympanostomy Tubes 9/29/2014
Exelixis, Inc. (EXEL) Announces Positive Results From Phase 3 Pivotal Trial Of Cobimetinib In Combination With Vemurafenib In Patients With BRAF V600 Mutation-Positive Advanced Melanoma 9/29/2014
Roche (RHHBY)’s Perjeta Regimen Extended The Lives Of People With An Aggressive Type Of Metastatic Breast Cancer By 15.7 Months Compared To Herceptin And Chemotherapy 9/29/2014
Helsinn Group Release: Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Shows Significant Increase In Lean Body Mass, Body Weight And Improved Symptoms 9/29/2014
Roche (RHHBY)’s Investigational Combination Of Cobimetinib Plus Zelboraf® (Vemurafenib) Provided Significant Benefit To People With Advanced Melanoma Over Zelboraf Alone 9/29/2014
Provectus Biopharmaceuticals Inc. Data Presented At ESMO 2014 Congress Show Ablative, Bystander Effects Of PV-10 9/29/2014
Bristol-Myers Squibb Company (BMY) Positive Phase 3 Data For Opdivo (Nivolumab) In Advanced Melanoma Patients Previously Treated With Yervoy (Ipilimumab) Presented At The ESMO 2014 Congress; First Phase 3 Results Presented For A PD-1 Immune Checkpoint Inhibitor 9/29/2014
Pfizer (PFE) Delays Start Of Phase 3 Rivipansel Trial, GlycoMimetics, Inc. (GLYC) Shares Fall 9/26/2014
Novartis AG (NVS) Reports Two Positive Phase 3 Trials For Arthritis Drug 9/26/2014
Immunomedics, Inc. (IMMU) Publishes Results On Immunotherapy Of Solid Cancers Mediated By A Novel Bispecific Antibody 9/26/2014
Cempra Pharmaceuticals, Inc. Completes Enrollment Of Solitaire-Oral Phase 3 Trial 9/26/2014
Bausch & Lomb Announces Successful Results From Phase 3 Study Of Sub-Micron Loteprednol Etabonate Ophthalmic Gel, 0.38% 9/26/2014
Navidea Biopharmaceuticals (NAVB)’s Lymphoseek® Recommended By CHMP For European Approval In Sentinel Lymph Node Detection For Melanoma, Breast And Certain Head And Neck Cancers 9/26/2014
Nektar Therapeutics (CA) (NKTR) Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation 9/26/2014
Helsinn Announces That Pivotal Phase 3 Trial Data For Anamorelin In ROMANA 1 And 2 Studies In Non-Small Cell Lung Cancer Patients With Anorexia-Cachexia Will Be Presented At The 38th European Society For Medical Oncology (ESMO) Congress In 2014 9/25/2014
Radiant Research/Clinical Research Advantage, Inc. Enrolls More Than 8,000 Subjects For Hepatitis B Vaccine Study 9/25/2014
Roche (RHHBY)’s Avastin Prolongs Life In Breast Cancer Study 9/25/2014
NicOx SA (COX.PA) Gets Boost From Strong Prospects For Glaucoma Drug Vesneo 9/25/2014
Gilead Sciences, Inc. (GILD)'s Single Tablet HIV Regimen Meets Goals In Two Phase 3 Studies 9/25/2014
Braeburn Pharmaceutical' Probuphine® Study Hits Enrollment Milestone 9/24/2014
Lipocine Inc. (LPCN) Testosterone Therapy Meets Phase 3 Goals 9/24/2014
Egalet Announces Update On Clinical Development Plan For Abuse-Deterrent Morphine Egalet-001 9/24/2014
ZS Pharma (ZSPH) Announces Positive Top-Line Results From HARMONIZE (ZS004), A Second Phase 3 Clinical Trial Of ZS-9 In Patients With Hyperkalemia 9/24/2014
Lipocine Inc. (LPCN) To Host Conference Call And Webcast To Discuss Top-Line Results From The Phase 3 Study Of LPCN 1021 9/24/2014
ESMO 2014 To Feature New Oncology Data From Across Bayer HealthCare Pharmaceuticals (BAYA.F) Franchise 9/24/2014
Alnylam Pharmaceuticals (ALNY) Initiates DISCOVERY, A Screening Study Examining The Prevalence Of Transthyretin (TTR) Mutations In Patients Suspected Of Having Cardiac Amyloidosis 9/24/2014
Cerevast Therapeutics, Inc. Announces Outcome Of First Interim Analysis Of Phase 3 CLOTBUSTER Trial For The Treatment Of Acute Ischemic Stroke 9/23/2014
Acceleron Pharma Provides Update On Externally Sponsored Clinical Trial Of Dalantercept Monotherapy In Ovarian Cancer 9/23/2014
Opko Health, Inc.'s Second Rayaldee Phase 3 Trial Meets Primary Endpoints 9/23/2014
Titan Pharmaceuticals (TTP) Announces Enrollment Reaches Halfway Mark In Phase 3 Study Of Probuphine For Opioid Dependence 9/23/2014
Alcobra (ADHD) Announces Completion Of All Patient Visits In Phase 3 Clinical Trial Of MDX In Adult ADHD 9/22/2014
CytRx Corporation (CYTR) Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress 9/22/2014
Tenax Therapeutics Announces First Patients Enrolled In Phase 3 LEVO-CTS Clinical Trial Of Levosimendan 9/22/2014
Elusys Therapeutics, Inc. Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 9/22/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Its Phase 3 Trial Of TH-302 In Patients With Advanced Soft Tissue Sarcoma Will Continue As Planned Following Protocol-Specified Interim Analysis 9/22/2014
TauRx Therapeutics Achieves Enrollment Target For Second Phase 3 Clinical Trial Of LMTX™ In Alzheimer's Disease 9/22/2014
Boston Therapeutics, Inc. Signs Clinical Trial Agreement With Prestigious Joslin Diabetes Center For Phase III Study Of BTI-320 9/22/2014
Dynavax Technologies Corporation (DVAX) Completes Enrollment Of Phase 3 Study Of HEPLISAV-B™ 9/22/2014
BioSpecifics Technologies Corporation (BSTC) Announces New MULTICORD And Retreatment Data For XIAFLEX® For Dupuytren's Contracture Presented At American Society For Surgery Of The Hand Annual Meeting 9/19/2014
BioTime (BTX) Announces Presentation Of Phase 3 Data At EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 9/19/2014
Transparency Life Sciences To Conduct Sarcoidosis Trial For Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) ' Kiacta™ Using Crowdsourcing And Telemonitoring 9/19/2014
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA 9/18/2014
Novo Nordisk A/S (NVO)'s Diabetes Drug Ryzodeg Effective In Phase 3b Study 9/18/2014
Enrollment In Argos Therapeutics, Inc. (ARGS)' Pivotal Phase 3 ADAPT Trial Of AGS-003 For Metastatic Renal Cell Carcinoma Surpasses Fifty Percent 9/18/2014
Eli Lilly and Company (LLY) Release: CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients 9/18/2014
Synergy Pharmaceuticals Reaches Halfway Mark For Second Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 9/18/2014
Merck & Co. (MRK)'s Long-Delayed Osteoporosis Drug Passes Trial 9/17/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Receives Positive Regulatory Feedback On ICT-107 Supporting Advancement To Registrational Phase 3 Testing In Newly Diagnosed Glioblastoma 9/17/2014
Achaogen (AKAO) Announces First Patient Enrollment In A Phase 3 Clinical Trial Of Plazomicin To Treat Infections Caused By Carbapenem-Resistant Enterobacteriaceae (CRE) 9/17/2014
Intarcia Therapeutics, Inc. Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 9/17/2014
Soligenix (SNGX) Announces FDA Clearance Of Phase 3 Clinical Protocol Of SGX301 In Cutaneous T-Cell Lymphoma 9/17/2014
Merck & Co. (MRK) Presents First Phase 3 Data In Japanese Patients For Omarigliptin, An Investigational Once-Weekly DPP-4 Inhibitor For Type 2 Diabetes 9/17/2014
Janssen-Cilag International NV (JNJ) Release: Analysis Of Pooled Data From Phase 3 Trial Results Show Glycaemic Efficacy Of INVOKANA® (Canagliflozin) Is Largely Independent Of Beta-Cell Function And Insulin Sensitivity In The Treatment Of Type 2 Diabetes In Adults 9/17/2014
Isis Pharmaceuticals, Inc. (ISIS) Earns $4 Million From Achaogen (AKAO) For The Initiation Of A Phase 3 Study Of Plazomicin 9/17/2014
Analyst: Safety Worries Dog Merck & Co. (MRK)’s Osteoporosis Drug 9/16/2014
Amgen (AMGN) Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis 9/16/2014
Bayer HealthCare Pharmaceuticals (BAYA.F) And Orion Corporation Initiate Phase 3 Trial Of ODM-201 In Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 9/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer 9/16/2014
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014
Boehringer Ingelheim Corporation Release: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction In Blood Glucose In Phase 3 Study 9/16/2014
Agile Therapeutics, Inc. Initiates Phase 3 SECURE Study For Twirla™ 9/16/2014
ZS Pharma (ZSPH) Presents New Data From ZS003 A Two Week Phase 3 Trial Demonstrating That ZS-9 Prevented Recurrence Of Hyperkalemia In Heart Failure Patients On RAASi 9/16/2014
Relypsa, Inc. (RLYP) Announces New Analysis Of Phase 3 Data Demonstrating Patiromer's Ability To Rapidly Correct, And Prevent Recurrence Of, Hyperkalemia In Heart Failure And Non-Heart Failure Patients 9/16/2014
Mylan Inc. (MYL) Commences Phase 3 Clinical Trials For Its Generic Version Of Advair Diskus® And Insulin Analog To Lantus® 9/16/2014
Roche (RHHBY) Starts Pivotal Late-Stage Trial For Eye Drug Lampalizumab 9/15/2014
Cardio3 BioSciences Receives Approval For The Continuation Of Its Chart-1 Phase III Clinical Trial From The DSMB 9/15/2014
Amgen (AMGN) Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9/15/2014
TG Therapeutics, Inc. (MHA) Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its First Phase 3 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Imbruvica(R) (Ibrutinib) For Patients With Previously Treated Chronic Lymphocytic Leukemia 9/15/2014
OSE Pharma Release: Texopi®, A New Ray Of Hope For Lung Cancer Immunotherapy 9/15/2014
Intarcia Therapeutics, Inc. Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q 9/12/2014
Detailed Results From Biogen Idec, Inc. (Massachusetts) (BIIB) And AbbVie (ABBV)’s Pivotal Phase 3 Decide Study Further Define The Efficacy And Safety Profile Of ZINBRYTA™ (Daclizumab High-Yield Process) 9/12/2014
Eli Lilly and Company (LLY)'s Cyramza Met Primary Endpoint In Phase 3 Study 9/12/2014
AbbVie (ABBV)'s Phase 3 Trial Of Humira Meets Primary Endpoint 9/12/2014
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Report Positive New Data From Lemtrada Multiple Sclerosis Trial 9/12/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance Of Efficacy And Safety In Multiple Sclerosis Patients 9/11/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New Data From ENDORSE Show Positive Results Continued Over Five Years With TECFIDERA® (Dimethyl Fumarate) In A Wide Range Of Multiple Sclerosis Patients 9/11/2014
ZS Pharma (ZSPH) To Present Data From Phase 3 Trial Of ZS-9 In Late-Breaking Session At Heart Failure Society Of America 18th Annual Scientific Meeting 9/11/2014
Mologen AG (MOLGF.PK): Initiation Of Phase 3 IMPALA Study With Immunotherapy MGN1703 In Colorectal 9/11/2014
GlaxoSmithKline (GSK) Takes Lead In New Wave Of Biotech Lung Drugs As Mepolizumab Performs In Phase 3 Study 9/10/2014
Thoratec Corporation (THOR) Announces Start Of Heartmate 3™ U.S. Clinical Trial 9/10/2014
Nymox Pharmaceutical (NYMX) Announces Positive Prostate Cancer 8 Month Clinical Trial Results 9/10/2014
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Manuscript Analyzing Cost Of Intravenous Patient-Controlled Analgesia With Opioids 9/10/2014
Eisai Inc. (ESALF.PK) Release: Lorcaserin HCl Data To Be Presented At The American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium 9/10/2014
SANUWAVE, Inc. Receives Information From The Data Monitoring Committee On The Dermapace Clinical Trial 9/10/2014
University of Minnesota Masonic Cancer Center Joins CEL-SCI (CVM)’s Phase 3 Head & Neck Cancer Trial 9/10/2014
Evoke Pharma, Inc. Announces The Completion Of Enrollment In Its Thorough ECG Study For EVK-001 9/9/2014
PTC Therapeutics, Inc. (PTCT) Completes Enrollment Of Landmark Trial In Duchenne Muscular Dystrophy 9/9/2014
Charleston Laboratories, Inc. Announces Key Clinical Updates For Novel Drugs 9/9/2014
Spectrum Pharmaceuticals, Inc. (SPPI) Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharmaceutical, Co., Ltd 9/9/2014
Vital Therapies, Inc. (VTI) (VTL) Announces Management Addition; Enrollment In VTI-208 Phase 3 Trial Now 75 Percent Complete 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports On PK Profile Of A Single Oral Dose Of Delafloxacin In Support Of U.S. Phase 3 Gonorrhea Program 9/8/2014
Relypsa, Inc. (RLYP) Announces Phase 3 Patiromer Data To Be Presented In Late-Breaking Session At Heart Failure Society Of America 18th Annual Scientific Meeting 9/8/2014
Skyepharma PLC (SKYEF)’s Partner Mundipharma AG Announces Results Of Pivotal Phase III Study For Flutiform® In Paediatric Asthma 9/8/2014
Celsion Corporation (CLSN) Announces Highlights From Three Presentations Given At The International Liver Cancer Association 2014 Annual Conference 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrate Delafloxacin's Potent And Rapid Antimicrobial Activity Against Neisseria Gonorrhoeae 9/8/2014
Evotec AG (EVTG.F) Announces Update On DiaPep277® 9/8/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Phase 3 Study Shows Investigational Tiotropium Improves Lung Function In Adolescent Patients With Symptomatic Asthma 9/8/2014
Successful Completion Of Phase 3 Program For Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Two More Phase Iii Studies Support The Benefits Of Reslizumab Treatment In Asthma Patients With Eosinophilia 9/8/2014
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014
Purdue Pharma L.P. Release: New Research Highlights An Investigational Single-Entity Formulation Hydrocodone Bitartrate Extended-Release Tablet At PAINWeek 9/8/2014
Sosei Group Corporation Announces Positive Results For Ultibro® And Seebri® Presented At ERS 2014, And Promotion Agreement With Pfizer Inc. (PFE) In The UK 9/8/2014
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Sufentanil Sublingual Tablet System Vs. Intravenous Patient-Controlled Analgesia With Morphine For Postoperative Pain Study Results 9/5/2014
Eli Lilly and Company (LLY)'s Diabetes Drug Trumps Sanofi (France) (SAN.PA)'s In Phase 3 Trials 9/5/2014
Exelixis, Inc. (EXEL) Chops 70 Percent Of Workforce After Prostate Drug Cabozantinib Fails Pivotal Study 9/4/2014
Novartis AG (NVS)'s New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales 9/4/2014
Flexion Therapeutics (FLXN) To Start FX006 Phase 3 Pivotal Trial In 2014; Following FDA Meeting, Development Plan Advanced By One Year 9/4/2014
Celgene Corporation (CELG) Release: Phase III FIRST™ (MM-020/IFM 07-01) Trial Of REVLIMID® (lenalidomide) Plus Dexamethasone In Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates For Stem Cell Transplant Published In New England Journal Of Medicine 9/4/2014
FDA Grants Fast Track Designation To Aradigm Corporation (ARDM)’s Pulmaquin For Non-Cystic Fibrosis Bronchiectasis 9/4/2014
Final Landmark Trial Confirms Efficacy Of Sanofi (France) (SAN.PA)'s Dengue Vaccine 9/3/2014
San Diego's ACADIA Pharmaceuticals, Inc. (ACAD) Wins FDA Breakthrough Therapy Designation For NUPLAZID™ 9/3/2014
RedHill Biopharma Ltd. (RDHL) Initiates Phase 3 Study Of RHB-102 For Gastroenteritis 9/3/2014
CEL-SCI (CVM) Enrolls 20 Patients In August In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 9/3/2014
Celsion Corporation (CLSN) Announces Enrollment Of First Patient In Global Phase 3 OPTIMA Study Of Thermodox® In Primary Liver Cancer 9/3/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Safety-Only Registration Trial in Canada Of Rhopressa™ In Patients With Glaucoma 9/3/2014
TetraPhase Pharmaceuticals Announces Positive Oral Dosing Data From Lead-in of IGNITE 2 Phase 3 Trial Of Eravacycline In cUTI Support Advancement To Pivotal Portion 9/3/2014
Daiichi Sankyo Company, Limited Release: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 9/3/2014
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
Hatchtech Announces Successful Phase 3 Study Results For Xeglyze™ Lotion 9/2/2014
Macrocure (MCUR) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Curexcell In Diabetic Foot Ulcers 9/2/2014
Sophiris Bio Inc. (SPHS) Reports Completion Of Enrollment In The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 9/2/2014
Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Delivers Clinically And Statistically Significant Reduction In Asthma Exacerbations In Two Pivotal Phase 3 Studies 9/2/2014
XBiotech USA, Inc. Halts Cancer Study On Positive Phase 3 Results 9/2/2014
Ampio Pharmaceuticals, Inc. (AMPE) Release: Update On The Phase 3 Multicenter, Double-Blind STEP Study Of Ampion™ For Osteoarthritis Of The Knee 9/2/2014
Birken Announces Positive Results Of Phase 3 Trials With Oleogel-S10 For Accelerated Wound Healing In Patients With Partial Thickness Wounds 9/2/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-APOCIII Rx In Patients With FCS 8/28/2014
FDA Grants Amgen (AMGN) Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 8/27/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
Regado Biosciences, Inc. (RGDO) Permanently Halts Enrollment In Lead Drug Trial 8/26/2014
ZS Pharma (ZSPH) To Present Late-Breaking Abstract Data From Phase 3 Trial Of ZS-9 In State Of The Art And Featured Research Session Oral Presentation At European Society of Cardiology Congress 8/26/2014
The Neurocritical Care Society Announces Trial Results & New Guidelines At Their 2014 Annual Meeting 8/26/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
La Jolla Pharmaceutical Company (LJPC) Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome 8/25/2014
Adocia Launches Phase III Clinical Study In India Of Treatment For Diabetic Foot Ulcer 8/25/2014
Janssen Research & Development Release: Data on XARELTO® At ESC Congress 2014 Hot Line Session Premieres First Prospective Study Of A Factor Xa Inhibitor In Elective Cardioversion 8/25/2014
Update: OncoGenex Pharmaceuticals Inc. (OGXI) Phase 3 ENSPIRIT Trial Continuing As Planned 8/22/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/21/2014
Eli Lilly and Company (LLY)'s Psoriasis Drug Ixekizumab Succeeds In Late-Stage Studies 8/21/2014
Long-Acting Version Of Baxter International, Inc. (BAX)'s Hemophilia A Drug BAX 855 Succeeds In Study 8/21/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/20/2014
CEL-SCI (CVM) Expands Its Global Phase 3 Immunotherapy Head And Neck Cancer Trial Into Centre Hospitalier Universitaire De Quebec In Canada 8/19/2014
Actavis (ACT) Reports Positive Top-Line Data From Two Ceftazidime-Avibactam Late-Stage Trials 8/19/2014
Auspex Pharmaceuticals Completes Enrollment In Phase 3 Registration Clinical Trial Of SD-809 In Chorea Associated With Huntington's Disease 8/18/2014
Amgen (AMGN) Drops After Hours On Failed Phase 3 Multiple Myeloma Trial 8/18/2014
Supernus Pharmaceuticals (SUPN) Snags FDA Fast Track Designation For ADHD Drug SPN-810 8/15/2014
FDA Accepts CorMedix (CRMD) Pivotal Phase 3 Study Protocol 8/15/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Taxus Cardium (CRXM) Announces Biological And Clinical Advances In Angiogenic Gene Therapy For Heart Disease In Journal Of Cardiovascular Pharmacology 8/13/2014
Cardium Therapeutics, Inc. (CXM) Announces Review In Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 8/13/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014
Cempra Initiates Phase 3 Clinical Trial In Patients With Uncomplicated Gonorrhea Infection 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Salix Pharmaceuticals, Ltd. (SLXP) Announces Important Topline Results For Microbiome, Culture & Susceptibility, And Key Secondary Efficacy Results For TARGET 3, Rifaximin IBS-D Repeat Treatment Study 8/12/2014
Opko Health, Inc. Release: Rayaldee Phase 3 Trial Meets Primary Endpoints 8/12/2014
Tolero Pharmaceuticals And Eutropics Pharmaceuticals Announce Data Demonstrating Clinical Utility Of Praedicare Dx In Guiding New Drug Treatment Of CLL Patients 8/12/2014
Evoke Pharma, Inc. Announces Initiation Of A Thorough ECG (QT) Study For EVK-001 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Provides Updates On Progress Of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 8/11/2014
Northwest Biotherapeutics (NWBO) Provides Update About Phase 3 Dcvax®-L Trial For Gbm And "Information Arm" Compassionate Use Patients 8/11/2014
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014
Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia 8/11/2014
Collegium Pharmaceutical, Inc. Announces Positive Top-Line Data From Phase III Study of Oxycodone DETERx®, Its Abuse-Deterrent, Extended-Release Product For Chronic Pain 8/7/2014
CTI BioPharma Granted Fast Track FDA Status For Pacritinib 8/7/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
BioDelivery Sciences International (BDSI) Provides Update On Ongoing Phase 3 Pivotal Trial For Clonidine Topical Gel For Painful Diabetic Neuropathy 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Concordia Healthcare Corp (CXR.TO) Initiates Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 8/5/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
XBiotech USA, Inc. Enrolls First Patient In Phase III European Registration Study Using Xilonix™ For Treatment Of Colorectal Cancer 8/4/2014
Mologen AG (MOLGF.PK): First Approvals For Phase III IMPALA Colorectal Cancer Study 8/4/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy 8/1/2014
CEL-SCI (CVM) Achieves Milestone In July With Total Of 232 Patients Enrolled To Date In Its Phase 3 Head And Neck Cancer Trial 8/1/2014
New Data On Chimerix, Inc. (CMRX)'s brincidofovir Supports Safety And Antiviral Activity Against Multiple Life-Threatening DNA Viruses In Organ Transplant Recipients 7/31/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Post-Hoc Analyses Of Lorcaserin Phase 3 Clinical Trial Results In Obesity 7/30/2014